On May 28, PegBio Pharma (02565.HK) rose 10.77% in regular trading, trading at HK$10.1/share, with trading volume of HK$35.96 million.

On the news front, the stock experienced a sharp technical rebound following the previous session's steep selloff triggered by the full expiration of the IPO lock-up period. On May 27, the stock plunged as much as 15.99% as the company marked its one-year listing anniversary, with all pre-IPO shareholders' restricted shares becoming eligible for sale simultaneously. The concentrated release of low-cost shares created intense selling pressure, driving the stock to an intraday low of HK$8.78. With the bulk of lock-up expiry selling pressure largely absorbed in the prior session, the stock staged a recovery as bargain hunters stepped in.

PegBio Pharma is a biotechnology company focused on chronic metabolic diseases. Its core product PB-119 is a near-commercialization long-acting GLP-1 receptor agonist primarily targeting Type 2 diabetes and obesity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)